|
|
Article: Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research.
- Article from:
- PR Newswire
- Article date:
- April 23, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (BULLETIN BOARD: LIXT) announced today that Dr. Jie Lu and Dr. Zhengping Zhuang of the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and its collaborator, Lixte Biotechnology Holdings. Inc., reported at the Annual Meeting of the American Association of Cancer Research that its lead compound LB-1, one of a patent-pending proprietary series of agents, has anti-cancer activity against human glioblastoma multiforme cells in a mouse model of cancer. Glioblastoma multiforme is the most common and ...
Related newspaper, magazine, and journal articles:
|
|
Article: Lixte Biotechnology Holdings' Lead Compound, ...
PR Newswire;
July 2, 2009 ;
700+ words
... ... PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (BULLETIN BOARD: LIXT) announced ... cancer types in patients." About Lixte Biotechnology Holdings, Inc.: Lixte Biotechnology Holdings, Inc. is a cancer therapeutics ...
|
|